Overview

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Status:
Completed

Trial end date:
2018-03-07

Target enrollment:

Participant gender:

Summary

The objective of this study was to assess the safety and tolerability, including the maximum tolerated dose, of gilteritinib in participants with relapsed or treatment-refractory acute myeloid leukemia (AML). This study also determined the pharmacokinetic (PK) parameters of gilteritinib.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Astellas Pharma Global Development, Inc.

Treatments:

Cephalexin
Midazolam
Voriconazole